Vitalize secured a $31 million Series A focused on helping hospitals manage labor and capacity, positioning the product around operational scheduling rather than clinical workflows. The round was led by Oak HC/FT with participation from a broad set of investors including Norwest and Rock Health Capital. For biotech-adjacent stakeholders, the emphasis on hospital throughput and staffing capacity can indirectly affect clinical trial site performance and patient access. Investors will likely watch adoption and how quickly it integrates into existing hospital scheduling systems.